Skip to main content

KRYS SHAREHOLDER INVESTIGATION: Levi & Korsinsky Notifies Investors of Potential Securities Claims Involving Krystal Biotech, Inc.

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

NEW YORK CITY, NY / ACCESS Newswire / November 19, 2026 / Krystal Biotech (NASDAQ: KRYS) shareholders lost $36.39 per share on November 2, 2026, when the stock fell 10.95% to close at $295.90 after the Company said data releases for several of its product candidates would slip to 2027. If you suffered a loss on your Krystal Biotech investment, you are encouraged to click here to submit your information. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.

The timing disclosure came alongside Krystal Biotech's operating and financial results for the third quarter ended September 30, 2026, announced on November 2, 2026. Earlier, the Company had told investors that the data in question would be available by the end of 2026.

Levi & Korsinsky is investigating whether Krystal Biotech and certain of its officers or directors may not have adequately disclosed the status of these product candidate timelines, and whether investors were exposed to potential securities law violations.

Investors who purchased Krystal Biotech shares and suffered losses can have their KRYS losses evaluated at no cost or reach Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500.

WHY LEVI & KORSINSKY -- Ranked in ISS Securities Class Action Services' Top 50 Report for seven consecutive years, Levi & Korsinsky, LLP is a nationally recognized leader in shareholder rights litigation. With a team of over 70 professionals, the firm has recovered billions of dollars for investors.

Frequently Asked Questions About the KRYS Investigation

Q: What is the KRYS securities fraud investigation about?
A: A securities investigation is pending concerning Krystal Biotech, Inc. (NASDAQ: KRYS) regarding potentially materially false or misleading statements. Shares fell approximately 10.95% after the Company disclosed that data releases for several product candidates would not come until 2027, causing losses for shareholders.

Q: Who is eligible to participate in the KRYS investigation?
A: Investors who purchased KRYS stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.

Q: Who is conducting the KRYS investigation?
A: Levi & Korsinsky, LLP is investigating potential securities fraud claims on behalf of investors who purchased KRYS securities. The firm is nationally recognized, ranked in the ISS Top 50 for seven consecutive years, and has recovered billions of dollars for aggrieved investors.

Q: What do KRYS investors need to do right now?
A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery. No immediate action is required to remain eligible to participate in the investigation.

Q: What is a lead plaintiff and why does it matter?
A: If the investigation proceeds to legal action, a lead plaintiff is the investor the court appoints to represent the group of affected investors. Lead plaintiffs are typically investors with the largest documented losses. Contacting the firm during the investigation phase preserves that option.

Q: What if I already sold my KRYS shares -- can I still recover losses?
A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought KRYS and sold at a loss may still participate in the investigation.

Q: What if my KRYS losses are small -- is it still worth contacting a lawyer?
A: Yes. There is no minimum loss amount required to participate in the investigation.

Q: What does it cost me to participate?
A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in any resulting action, these matters are generally handled on a contingency basis, with any attorneys' fees and expenses subject to court approval.

Attorney Advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171

SOURCE: Levi & Korsinsky, LLP



View the original press release on ACCESS Newswire

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  259.17
-8.57 (-3.20%)
AAPL  348.71
-3.74 (-1.06%)
AMD  480.62
-49.52 (-9.34%)
BAC  48.54
-0.37 (-0.76%)
GOOG  275.62
-3.58 (-1.28%)
META  599.04
-17.34 (-2.81%)
MSFT  502.48
-5.81 (-1.14%)
NVDA  148.24
-2.72 (-1.81%)
ORCL  111.45
-2.44 (-2.14%)
TSLA  376.14
-7.58 (-1.98%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.